AFP and liver cancer: Furthermore, miR-26a, driven by a hAFP (human alpha fetoprotein) -hTERT (human telomerase reverse transcriptase) dual promoter, was found to specifically decrease the viability of liver cancer cells by regulating estrogen receptor, progesterone receptor and p53 (but not cyclin D2 or cyclin E2) in vitro and in vivo [60].